Josey John A. 4

What Happened

• Josey John, a director of Day One Biopharmaceuticals (DAWN), disposed of a total of 272,508 shares on April 23, 2026. These dispositions were to the issuer in connection with the company’s acquisition by Servier.
• The merger consideration was $21.50 per share, so the aggregate cash value realized was approximately $5,858,922. Several of the reported dispositions were derivative securities (options and RSUs) that were converted into cash as part of the merger.

Key Details

• Transaction date: April 23, 2026. Filing date (Form 4): April 23, 2026 (timely).
• Price per share / merger consideration: $21.50 (per Merger Agreement). Total proceeds ≈ $5.86M.
• Total shares disposed: 272,508 (breakdown in filing includes both common shares and several derivative conversions).
• Shares owned after transaction: All outstanding common shares, options and RSUs were converted/cancelled pursuant to the merger; the filing indicates the securities were cashed out at closing.
• Notable footnotes:
  • F1–F2: Day One was acquired by Servier; each share was purchased or converted into the right to receive $21.50/share.
  • F3–F4: Outstanding options were fully vested (or accelerated), and unvested options/RSUs were accelerated and then canceled and converted into cash equal to the merger consideration (options paid the spread over exercise price).
• Transaction code: Disposition to issuer (D) — not an open-market sale but the deal closing payout.

Context

• These are merger cash-outs, not routine open-market sales. Derivative items (options/RSUs) were accelerated and settled for cash per the acquisition terms, which is common in deal closings.
• This filing is informational about the payout from the acquisition; it does not necessarily signal trading intent beyond the merger consideration.